Antigen-Specific vs. Neutralizing Antibodies Against Conditioned Media of Patients With Clostridioides difficile Infection: A Prospective Exploratory Study

The immunological response against Clostridioides difficile (C. difficile) is crucial for an improved understanding of disease mechanisms and the development of novel therapeutic strategies. From April 2014 to February 2015, adult patients with C. difficile infection (CDI) were recruited, and the clinical course and treatment response were carefully monitored. On day 1, 3, and 6 after diagnosis, patient plasma samples were screened for anti-GDH (glutamate dehydrogenase), anti-TcdA, anti-TcdB, and anti-CWP84 (cell-wall protein 84) antibodies by ELISA. Additionally, neutralization assays of toxins from conditioned media of clinical isolates (RT010, RT014, and RT027) were performed. Most patients with CDI (n = 46) had antibodies against GDH (85%) and CWP84 (61%), but only few had antibodies against TcdA (11%) and TcdB (28%). We found patients with neutralizing antibodies against C. difficile toxins (conditioned media) produced by RT027 (26%). A subgroup of these samples could neutralize both toxins from RT027 and RT014 [11%, (5/46)]; however, no single sample neutralized only RT014. Overall, neutralizing antibody titers were low (≤1:16). In a one week follow-up of acute infection, we never observed an early booster effect with seroconversion or antibody increases, irrespective of disease severity. No correlation was found between the presence of antigen-specific (ELISA) or neutralizing antibodies and the clinical course of disease. Anti-TcdB but not anti-TcdA antibodies correlated with the occurrence of neutralizing antibodies. In conclusion, natural antibody titers against C. difficile toxins were absent or low and were not associated with disease severity. The correlation between the anti-TcdB with toxin neutralization confirms the importance of TcdB for virulence of CDI. Alternative sensitization strategies, e.g., through vaccine development, are required to overcome the regular low-titer antibody production following natural intestinal C. difficile exposure.

[1]  V. Young,et al.  Anti-toxin antibody is not associated with recurrent Clostridium difficile infection. , 2020, Anaerobe.

[2]  Judong Shen,et al.  Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  N. Kitchin,et al.  A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Dübel,et al.  Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile , 2018, Front. Microbiol..

[5]  Stuart Johnson,et al.  Bezlotoxumab , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Mahfouz,et al.  Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon. , 2018, International journal of medical microbiology : IJMM.

[7]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Edmiston,et al.  Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. , 2017, Surgery.

[9]  C. von Eichel-Streiber,et al.  Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors. , 2016, Anaerobe.

[10]  Mark A. Miller,et al.  Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Cobo,et al.  Clostridium difficile Infection in Special High-Risk Populations , 2016, Infectious Diseases and Therapy.

[12]  I. Kiss,et al.  Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. , 2016, Vaccine.

[13]  A. Therien,et al.  Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling , 2014, Antimicrobial Agents and Chemotherapy.

[14]  T. Louie,et al.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  T. Norén,et al.  IgG Antibody Response to Toxins A and B in Patients with Clostridium difficile Infection , 2012, Clinical and Vaccine Immunology.

[16]  I. Brukner,et al.  Host and pathogen factors for Clostridium difficile infection and colonization. , 2011, The New England journal of medicine.

[17]  C. Kelly,et al.  The host immune response to Clostridium difficile. , 2011, Journal of medical microbiology.

[18]  Edward W. Tate,et al.  Roles of Cysteine Proteases Cwp84 and Cwp13 in Biogenesis of the Cell Wall of Clostridium difficile , 2011, Journal of bacteriology.

[19]  J. Starr,et al.  Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. , 2008, Journal of medical microbiology.

[20]  M. Rupnik.  Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. , 2008, FEMS microbiology reviews.

[21]  C. Surawicz,et al.  Clostridium Difficile Disease , 2007 .

[22]  Michael C. Wendl,et al.  Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.

[23]  S. Péchiné,et al.  Variability of Clostridium difficile Surface Proteins and Specific Serum Antibody Response in Patients with Clostridium difficile-Associated Disease , 2005, Journal of Clinical Microbiology.

[24]  Jon Brazier,et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.

[25]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[26]  P. Bidet,et al.  Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. , 1999, FEMS microbiology letters.

[27]  R. Fekety,et al.  Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. , 1994, Diagnostic microbiology and infectious disease.

[28]  R. Yolken,et al.  Serum antibody response to toxins A and B of Clostridium difficile. , 1983, The Journal of infectious diseases.

[29]  B. Girinathan,et al.  Clostridium difficile glutamate dehydrogenase is a secreted enzyme that confers resistance to H2O2. , 2014, Microbiology.

[30]  L. Gonzales.  Clostridium difficile , 2010, Methods in Molecular Biology™.